Monte Rosa Therapeutics (GLUE) Revenue (2024 - 2026)

Monte Rosa Therapeutics' Revenue history runs 3 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Revenue fell 94.94% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 97.3% YoY), while the FY2025 annual figure was $123.7 million, up 63.54% from the prior year.
• Revenue for Q1 2026 stood at $4.3 million, up from $2.8 million in the prior quarter.
• The five-year high for Revenue was $150.0 million in Q3 2025, with the low at $1.1 million in Q1 2024.
• The 3-year median for Revenue is $9.2 million (2024), against an average of $50.9 million.
• Peak annual rise in Revenue reached 7882.05% in 2025, while the deepest fall reached 95.41% in 2025.
• Monte Rosa Therapeutics' Revenue stood at $60.6 million in 2024, then slumped by 95.41% to $2.8 million in 2025, then jumped by 54.62% to $4.3 million in 2026.
• Business Quant data shows GLUE's Revenue at $4.3 million in Q1 2026, $2.8 million in Q4 2025, and $150.0 million in Q3 2025.